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Graft-versus-host disease (GVHD) is a major transplantation complication. The purpose of this study was to
measure immune cell subsets by ﬂow cytometry early after transplantation (before median day of GVHD
onset) to identify subsets that may play a role in GVHD pathogenesis. We also measured the subsets later after
transplantation to determine which subsets may be inﬂuenced by GVHD or its treatment. We studied 219
patients. We found that acute GVHD (aGVHD) was preceded by high counts of CD4 T cells and CD8 T cells. It
was followed by low counts of total and naive B cells, total and cytolytic NK cells, and myeloid and plas-
macytoid dendritic cells. Chronic GVHD (cGVHD) was preceded by low counts of memory B cells. In
conclusion, both CD4 and CD8 T cells appear to play a role in the pathogenesis of aGVHD. Generation of B cells,
NK cells, and dendritic cells may be hampered by aGVHD and/or its treatment. Memory B cells may inhibit the
development of cGVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION would suggest that these cells inﬂuence GVHD develop-
Graft-versus-host disease (GVHD) is the most important
complication of allogeneic hematopoietic cell transplanta-
tion (HCT), leading to substantial mortality and poor quality
of life. Multiple immune cell subsets, including subsets of
T cells, B cells, NK cells, monocytes/macrophages, and den-
dritic cells, have been implicated in the pathogenesis
of GVHD in animal models [1,2]. However, information is
limited on whether these subsets play a role in the patho-
genesis of GVHD in humans. Human studies depleting
certain immune cell subsets from the graft or correlating
numbers of immune cell subsets in the graft with the
likelihood of developing GVHD have suggested a pro-GVHD
role of T cells and B cells and anti-GVHD role of monocytes
or invariant NKT cells [3-9]. These studies would be com-
plemented by studies correlating numbers of immune cell
subsets in the HCT recipient after transplantation, before the
development of GVHD. However, only a few such studies
have been reported [4,10-13], all using small numbers of
patients, which precluded discovery-to-validation study
design; thus, spurious associations may have been reported.
Here, we enumerated multiple immune cell subsets in
the grafts and in the blood at predeﬁned time points after
transplantation in a large number of patients. Our main
objective was to identify associations between early post-
transplantation immune cell subset counts (before GVHD
onset) and GVHD. We reasoned that such associationsedgments on page 461.
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between GVHD and immune cell subset counts at later time
points (after GVHD onset). Such associations would suggest
subsets inﬂuenced by GVHD and/or its treatment.
As we focused on clinically signiﬁcant GVHD, we
primarily compared the subset counts in patients with
grade 0 to 1 versus 2 to 4 (signiﬁcant) acute GVHD (aGVHD),
and in patients with none or insigniﬁcant (not treated
with systemic immunosuppressive therapy) versus signiﬁ-
cant (treated with systemic immunosuppressive therapy)
chronic GVHD (cGVHD). First, in a discovery cohort, we
determined for each subset whether there is an association
with signiﬁcant aGVHD or signiﬁcant cGVHD. Second, all
statistically signiﬁcant associations from the discovery
cohort analysis were subjected to validation in a validation
cohort of patients of similar demographic and clinical
characteristics. Third, we compared the subset counts in
patients with grade 0 versus grade 2 to 4 aGVHD and in
patients with no cGVHD versus signiﬁcant cGVHD. This was
done using only 1 combined discovery and validation
cohort, as statistical power would be very limited if we used
the discovery-to-validation design for this question.
As immune cells are suspected to play a role in not only
GVHD but also in graft-versus-leukemia reaction, we also
determined for each subset whether there is an association
with relapse. As GVHD and relapse are the 2 most important
causes of post-transplantationmortality, we also determined
for each subset whether there is an association with death.
METHODS
Patients and Transplantation
For the discovery cohort, we studied 133 consecutive patients who
underwent ﬁrst allogeneic marrow or ﬁlgrastim-mobilized blood stem cellTransplantation.
Table 1
Patient Characteristics
Characteristic Discovery Cohort Validation Cohort Sig. of Difference*
No. of patients 133 86
Patient age, median (range), yr 47 (19-66) 50 (19-66) .164
Donor age, median (range), yr 35 (15-67) 37 (12-68) .786
Patient sex 79 M, 54 F (59% M, 41% F) 50 M, 36 F (58% M, 42% F) .853
Donor sex 89 M, 44 F (67% M, 33% F) 48 M, 38 F (56% M, 44% F) .097
Diagnosis/disease stage at transplantationy
Poor risk 58 (44%) 38 (44%) .933
Good risk 75 (56%) 48 (56%)
Diagnosis
AML in ﬁrst remission 42 (32%) 27 (31%) .007
AML beyond ﬁrst remissionz 16 (12%) 10 (12%)
ALL in ﬁrst remission 10 (8%) 12 (14%)
ALL beyond ﬁrst remission 5 (4%) 5 (6%)
CML in ﬁrst chronic/accelerated phase 8 (6%) 0
CML in blast or second chronic/accelerated phase 2 (w1%) 0
CMML 5 (4%) 0
CLL 2 (w1%) 7 (8%)
Non-Hodgkin’s lymphoma 21 (16%) 7 (8%)
Hodgkin’s lymphoma 2 (w1%) 0
Myelodysplasia/myeloﬁbrosis 14 (11%) 17 (20%)
Aplastic anemia 4 (3%) 0
Otherx 2 (w1%) 1 (1%)
Stem cell source
Bone marrow 8 (6%) 0 .020
Blood stem cells 125 (94%) 86 (100%)
Donor/recipient CMV serostatus at HCT
Positive/positive 37 (28%) 28 (33%) .687
Positive/negative 11 (8%) 7 (8%)
Negative/positive 30 (23%) 19 (22%)
Negative/negative 54 (41%) 27 (31%)
Unknown or indeterminate 1 (w1%) 5 (6%)
Donor/recipient EBV serostatus at HCT
Positive/positive 117 (88%) 65 (76%) .106
Positive/negative 4 (3%) 7 (8%)
Negative/positive 9 (7%) 9 (10%)
Negative/negative 0 1 (1%)
Unknown or indeterminate 3 (2%) 4 (5%)
Conditioning (in addition to ATG)
Fludarabine þ busulfan 44 (33%) 27 (31%) .058
Fludarabine þ busulfan þ TBI 81 (61%) 59 (69%)
Otherk 8 (6%) 0
Donor type
HLA-matched sibling 64 (48%) 37 (43%) .460
Other{ 69 (52%) 49 (57%)
Acute GVHD by grade
None 59 (44%) 33 (38%) .138
Grade 1 34 (26%) 32 (37%)
Grade 2 27 (20%) 12 (14%)
Grade 3 12 (9%) 5 (6%)
Grade 4 1 (w1%) 3 (3%)
Indeterminate 0 1 (1%)
Acute GVHD grade 2-4 developing
before the day 28 blood draw
16 (12%) 3 (3%) .044
Chronic GVHD
None 72 (54%) 44 (51%) .091
Not needing systemic therapy 13 (10%) 15 (17%)
Needing systemic therapy 48 (36%) 27 (32%)
Chronic GVHD needing systemic
therapy developing before
the day 84 blood draw
3 (2%) 0 .141
Relapse 26 (20%) 18 (21%) .868
Second malignancy# 11 (8%) 5 (6%) .495
Death 41 (31%) 27 (31%) .929
Follow-up (days after transplantation), median (range)
For GVHD or relapse** 795 (38-1657) 512 (34-1027) <.001
For GVHD or relapse among patients
without relapse/second malignancy/death
1034 (181-1532) 641 (68-1027) <.001
For death 835 (59-1657) 546 (44-1027) <.001
For death among surviving patients 1018 (181-1532) 650 (68-1027) <.001
Actual blood draw days after transplantation, median (range)
Projected day 28 28 (23-36) 27 (23-34) .025
Projected day 56 56 (50-68) 55 (51-64) .172
Projected day 84 84 (77-105) 83 (75-86) .028
(Continued)
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Table 1
(Continued)
Characteristic Discovery Cohort Validation Cohort Sig. of Difference*
Projected day 180 182 (160-200) 181 (159-207) .860
No. patients studied at time point
Projected day 28 113 81 Not applicable
Projected day 56 114 78 Not applicable
Projected day 84 112 74 Not applicable
Projected day 180 74 57 Not applicable
AML indicates acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CLL, chronic
lymphocytic leukemia; CMV, cytomegalovirus; EBV, Epstein-Barr virus; M, male; F, female; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; TBI,
total body irradiation.
* Determined by Mann-Whitney (Wilcoxon) test for ordinal variables and by chi-square test for nominal variables.
y Good risk disease was deﬁned as acute leukemia in ﬁrst remission, chronic myeloid leukemia in ﬁrst chronic or accelerated phase, myelodysplasia with<5%
marrow blasts or aplastic anemia. All other diseases/disease stages were considered poor risk.
z Includes any AML that evolved from myelodysplasia or myeloﬁbrosis.
x Acute undifferentiated leukemia (n ¼ 1, discovery cohort), unclassiﬁable myeloproliferative syndrome (n ¼ 1, discovery cohort), myeloproliferative syn-
drome (n ¼ 1, validation cohort).
k Combinations of cyclophosphamide, etoposide, melaphalan, or TBI.
{ Includes 10/10 (HLA-A,B,C,DRB1,DQB1)-allele matched unrelated donors (n ¼ 48 discovery cohort, n ¼ 40 validation cohort), 9/10-allele matched unrelated
donors (n ¼ 18 discovery, n ¼ 7 validation), 8/10-allele-matched unrelated donors (n ¼ 2 discovery, n ¼ 1 validation), 10/10-allele matched related nonsibling
donor (n ¼ 0 discovery, n ¼ 1 validation), or 9/10-allele matched related donors (n ¼ 1 discovery, n ¼ 0 validation).
# Including post-transplantation lymphoproliferative disorder. Excluding nonmelanoma skin cancer and carcinoma in situ.
** Follow-up for GVHD or relapsewas until relapse, secondmalignancy (including post-transplantation lymphoproliferative disorder; excluding nonmelanoma
skin cancer or carcinoma in situ), death or last contact, whichever occurred ﬁrst. The reason for ending follow-up at relapse or second malignancy was that the
treatment of relapse or second malignancy inﬂuences the risk of GVHD or relapse. Follow-up for death was until death or last contact, whichever occurred ﬁrst.
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the validation cohort, we studied 86 patients who underwent ﬁrst allo-
geneic transplantation in Calgary between September 2008 and August
2010. Patients were excluded if they developed graft failure or relapsed by
day 30. No patient developed graft failure after day 30. Table 1 displays
patient characteristics. The discovery and validation cohorts were similar,
except for there were more patients with chronic myeloid/myelomono-
cytic leukemia, patients receiving marrow and patients with early (before
day 28) aGVHD in the discovery cohort (Table 1). As expected, the
follow-up was longer in the discovery cohort (Table 1). Conditioning was
myeloablative, typically with ﬂudarabine (250 mg/m2), busulfan
(approximately 12.8 mg/kg i.v., pharmacokinetically adjusted), and
antithymocyte globulin (ATG, Thymoglobulin, 4.5 mg/kg), and additional
GVHD prophylaxis with methotrexate on day 1, 3, 6, and 11 and cyclo-
sporine from day -1 until 3 to 6 months after transplantation (longer in
case of chronic GVHD treated with systemic therapy) [14]. Conditioning of
some patients included total body irradiation (4 Gy) [15]. Supportive care
was similar for all patients. All blood products were cytomegalovirus
(CMV)-safe. CMV reactivation was treated pre-emptively [16]. Prophylaxis
of herpes simplex virus or varicella zoster virus disease with acyclovir/
valacyclovir was until 6 to 24 months after transplantation or longer (in
case of cGVHD treated with systemic immunosuppressive drugs). Moni-
toring of Epstein-Barr virus DNAemia was not done. No antibacterial or
antifungal prophylaxes were given routinely (except for trimethoprim-
sulfamethoxazole for Pneumocystis prophylaxis). Pneumocystis prophy-
laxis, typically using trimethoprim-sulfamethoxazole, was given until
6 months after transplantation or longer (in case of cGVHD treated with
systemic immunosuppressive drugs). Both aGVHD and cGVHD, if clinically
signiﬁcant, were treated with a corticosteroid with or without other
immunosuppressive modalities. Blood for the enumeration of immune cell
subsets was drawn on approximately day 28, day 56, day 84, and day 180
after transplantation (Table 1).
All patients enrolled in the study provided informed consent and the
research was approved by the University of Calgary Conjoint Health
Research Ethics Board.
Enumeration of Immune Cell Subsets
In the discovery cohort, heparinized blood (200 mL) or graft (20 mL) was
pipetted into 12  75 mm polystyrene tubes and washed in phosphate
buffered saline (PBS). Fluorochrome-labeled monoclonal antibody cocktails
were added to the cell pellet as follows:
(Tube 1) IgD-FITC/CD45-PE/CD19 þ CD20-ECD/CD27-PC5/CD5/PC7;
(Tube 2) CD11a-FITC/CD45RA-PE/CD3-ECD/CD8-PC5/CD4-PC7; (Tube 3)
TCR Vbeta11-FITC/TCR Valpha24-PE/CD3-ECD/CD24-PC5/CD4-PC7; (Tube 4)
CD56-FITC/CD14-PE/CD3-ECD/CD16-PC5; and (Tube 5) CD3þ16þ14þ19þ
56-FITC/CD11c-PE/HLADR-ECD/CD123-PC5/CD45-PC7.
All the antibodies were obtained from Beckman Coulter/Immunotech
(Miami, FL). Cells were incubated with the antibodies for 15 minutes at
room temperature. Erythrocytes were then lysed using an ammonium
chloride lysing solution and washed in PBS. Cells were resuspended in .5 mLof .1% formaldehyde in PBS (Polysciences, Warrington, PA). Flow cytometry
was performed on the same day, using a FC500 ﬂow cytometer (Beckman
Coulter, Hialeah, FL). During analysis of blood specimens using Winlist
software (Verity, Topsham, ME), mononuclear cells (MNCs) (lymphocytes
plus monocytes) were gated on forward versus side scatter plots. Percent-
ages of cell subsets were determined according to the deﬁnitions shown in
Table 2. For post-transplantation blood, each absolute cell subset count
was calculated as the absolute MNC count multiplied by the subset per-
centage (among total MNCs) divided by 100. The absolute MNC count rep-
resented the sum of the absolute lymphocyte count and the absolute
monocyte count, determined by a clinical hematology laboratory. Neutro-
phil counts were determined by a clinical hematology lab. For grafts, total
nucleated cells were gated on forward versus side scatter plots. Absolute cell
subset counts were calculated as the absolute nucleated cell count multi-
plied by the percentage of the cell subset among total nucleated cells,
divided by 100. Values per recipient body weight were used in subsequent
analyses. In the validation cohort, cryopreserved blood mononuclear cells
and cryopreserved grafts were used instead of fresh specimens. Otherwise,
the enumeration of the subsets was analogous to the discovery cohort.
Technicians determining the subset counts were blinded to the clinical
outcomes.
Deﬁnitions of Outcomes
Relapsewas deﬁned using standard criteria (eg,> 5% blasts in the case of
acute leukemia). Acute and chronic GVHD were diagnosed according to
historical criteria (acute if onset by day 100, and chronic if present after day
100). However, if a patient had diagnostic or distinctive features of cGVHD
[17] before day 100, the diseasewas classiﬁed as cGVHD (n¼ 7). Acute GVHD
was graded according to the 1994 consensus conference [18]. Chronic GVHD
was graded as none, not needing systemic immunosuppression (NNST,
roughly corresponding to limited cGVHD per Seattle criteria [19] or mild
cGVHD per NIH criteria [17]) and needing systemic immunosuppression
(NST, roughly corresponding to extensive cGVHD by Seattle criteria or
moderate to severe cGVHD byNIH criteria). From this point on, aGVHD refers
to grade 2 to 4 aGVHD, unless otherwise speciﬁed. Likewise, cGVHD refers to
cGVHD NST, unless otherwise speciﬁed.
Statistics
Counts of each immune cell subset listed in Table 2 were compared
betweenpatients with andwithout the outcome of interest (aGVHD, cGVHD,
relapse, or death) using the Mann-Whitney (Wilcoxon) (MWW) test. An
association was considered potentially signiﬁcant in univariate analysis
(UVA) if the MWW P value was <.05 (2-tailed). For associations considered
potentially signiﬁcant in UVA, multivariate analyses (MVA) were performed
using Cox regression analysis with Fine-Gray adjustment for competing
events (competing risk analysis) to determine whether patients with the
subset count above cutoff have higher or lower hazards of developing
the outcome independent of factors known to inﬂuence the outcome
(confounding factors). Cutoff values were determined for each subset
Table 2
Immune Cell Subset Deﬁnitions
Subset Deﬁnition
B cells CD19/20þ
Naïve B cells CD19/20þ mIgDþ CD27
Memory B cells, IgM/D/IgG/A/E nonswitched CD19/20þ mIgDþ CD27þ
Memory B cells, IgM/D/IgG/A/E switched CD19/20þ mIgD- CD27þ
CD4 T cells CD3þ CD4þ CD8-
Naïve CD4 T cells CD3þ CD4þ CD8- CD45RAhigh CD11alow/neg
Memory or effector CD4 T cells CD3þ CD4þ CD8- CD45RAlow/int CD11ahigh/int
CD8 T cells CD3þ CD4 CD8þ
Naïve CD8 T cells CD3þ CD4 CD8þ CD45RAhigh CD11alow/neg
Memory or effector CD8 T cells CD3þ CD4 CD8þ CD45RAlow/int CD11ahigh/int
CD4eCD8e T cells CD3þ CD4 CD8
CD4þCD8þ T cells CD3þ CD4þ CD8þ
NKT cells, invariant CD3þ Va24þ(high) Vb11þ
Monocytes CD14þ
Inﬂammatory monocytes CD14þ CD16-
Resident monocytes CD14þ CD16þ
NK cells CD16/56þ CD3 CD14
Regulatory NK cells CD16 CD56high CD3 CD14
Cytolytic NK cells CD16þ CD56int CD3- CD14
Myeloid dendritic cells HLADRhigh CD3 CD14 CD16 CD19 CD56 CD11cþ CD123
Plasmacytoid dendritic cells HLADRhigh CD3 CD14 CD16 CD19 CD56 CD11c CD123þ
Basophils HLADR CD3 CD14 CD16 CD19 CD56 CD123high
Neutrophils Determined by clinical hematology lab (not by ﬂow cytometry)
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curves (values associated with the highest sum of sensitivity and speciﬁcity
within the 10th to 90th interquartile range). Competing events for aGVHD or
cGVHD were relapse, second malignancy, or nonrelapse death. Confounding
factors for aGVHDwere recipient age (<45 and  45), donor age (<45 and 
45), donor type (HLA-matched sibling versus other) and donor/recipient
gender (male/male versus other). Confounding factors for cGVHD were
aGVHD, recipient age, donor age, donor type, donor/recipient gender, and
graft source (marrow versus blood). For relapse, the confounding factors
considered were signiﬁcant GVHD (grade 2 to 4 aGVHD or cGVHD needing
systemic therapy anytime) and disease stage (poor risk versus good risk, see
Table 1 footnotes for deﬁnitions). For death, confounding factors were
recipient age, donor age, and disease stage. In the MVA of the discovery
cohort, P  .01 was considered signiﬁcant. This was an arbitrary correction
for multiple comparisons; the correction was far less strict than Bonferroni
correction because we assumed that counts of the various immune cell
subsets were partly related to each other. For every association signiﬁcant in
the discovery cohort, the association was also analyzed by MVA in the
validation cohort. Associations signiﬁcant at P < .05 in the validation cohort
were considered to be validated (Table 3).
For some analyses (where indicated), the discovery and validation cohorts
were combined, eg, for the comparison of grade 0 versus grade 2 to 4 aGVHD
or no cGVHD versus cGVHD treated with systemic immunosuppressive
therapy (Table 4). In such cases, we ﬁrst performed UVA as above, and then (if
UVA P < .05) tested potentially signiﬁcant associations with MVA as above.
The associations were considered signiﬁcant if MVA P  .01.
The UVA analyses were performed using SPSS version 17.0 (SPSS Inc.
Released 2008. SPSS Statistics for Windows, Version 17.0. Chicago, IL). The
multivariate analyses were performed using Stata version 11 (StataCorp.
2009. Stata Statistical Software: Release 11. College Station, TX).RESULTS
Acute GVHD
Among 60 patients who developed aGVHD (grade 2 to 4),
the median onset of aGVHD was day 34 (range, 13 to 99).
Thus, associations between subset counts on day 28 and
aGVHD were suggestive of these subsets playing a role in
the pathogenesis of aGVHD, whereas associations between
aGVHD and subset counts on days 56, 84, or 180 were
suggestive of these subsets being inﬂuenced by aGVHD and/
or its treatment. As stated in Methods, all patients received
ATG, which is likely the cause of the relatively late median
onset of aGVHD in our cohort.
In the discovery cohort, high counts of the following
subsets on day 28 were associated with aGVHD: CD4 T cells,naive CD4 T cells, memory/effector CD4 T cells, CD8 T cells,
naïve CD8 T cells, memory/effector CD8 T cells, and
CD4eCD8e T cells. Acute GVHD was associated with low
counts of the following subsets at later time points: B cells
on days 56 and 84, naive B cells on days 56 and 84, non-
switched memory B cells on day 84, CD4 T cells on day 84,
naive CD4 T cells on days 180, memory/effector CD4 T cells
on day 84, CD4eCD8e T cells on day 84, NKT cells on day 84,
resident monocytes on day 84, NK cells on day 56, regula-
tory NK cells on days 56 and 84, cytolytic NK cells on day 56,
CD16highCD56e NK cells on day 56, myeloid dendritic cells
(MDCs) on day 84, plasmacytoid dendritic cells (PDCs) on
days 28, 56 and 84, basophils on days 56 and 84, and neu-
trophils on day 56. Acute GVHD was not associated with
high or low content of any subset in the graft.
In the validation cohort, associations between high subset
counts on day 28 and aGVHD were conﬁrmed for the
following subsets: CD4 T cells, memory/effector CD4 T cells,
CD8 T cells, and memory/effector CD8 T cells (Table 3,
Supplemental Figure 1). Associations between aGVHD and
low subset counts at later time points were conﬁrmed for the
following subsets: B cells on days 56 and 84, naive B cells on
days 56 and 84, nonswitched memory B cells on day 84, NK
cells on days 56, cytolytic NK cells on day 56, MDCs on day
84, PDCs on days 56 and 84, and basophils on day 84 (Table 3,
Supplemental Figure 2).
We also attempted to determine which subset counts
were associated with the most severe form of aGVHD, grade
3 to 4 aGVHD. We performed the above analyses for grade
3 to 4 versus grade 0 to 2 aGVHD. Because of a small number
of patients developing grade 3 to 4 aGVHD, meaningful
analyses were possible only when the discovery and vali-
dation cohorts were combined. Consistent with our ﬁndings
on grade 2 to 4 aGVHD, high counts of the following subsets
on day 28 appeared associated with grade 3 to 4 aGVHD:
CD4 T cells, naïve CD4 T cells, memory/effector CD4 T cells,
CD8 T cells, and memory/effector CD8 T cells. In addition,
high day 28 counts of total B cells, naïve CD8 T cells,
CD4eCD8e T cells, and low day 28 counts of regulatory NK
cells were associated with grade 3 to 4 aGVHD
Table 3
Associations between Immune Cell Subset Counts and aGVHD or cGVHD
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
Associations shown are those signiﬁcant in competing risks multivariate analysis in both discovery and validation cohorts. [ indicates high subset count
associated with GVHD, Y indicates low subset count associated with GVHD. All associations remained signiﬁcant after removing patients who developed aGVHD
or cGVHD before or after the blood draw date (ie, for associations at early time points (day 28 for aGVHD, and day 28, day 56, and day 84 for cGVHD). Patients
developing GVHD before the time point were removed; for associations at late time points (day 56, day 84, and day 180 for aGVHD, and day 180 for cGVHD),
patients developing GVHD after the time point were removed).
* aGVHD comparison was grade 2 to 4 versus grade 0 to 1.
y cGHVD comparison was for those needing systemic immunosuppressive therapy versus none or those not needing systemic immunosuppressive therapy.
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grade 3 to 4 aGVHD and subset counts at later time points,
consistent with our ﬁndings on grade 2 to 4 aGVHD, grade 3
to 4 aGVHDwas associated with low counts of B cells on day
84, naïve B cells on days 56 and 84, nonswitched memoryB cells on day 84, MDCs on day 84, PDCs on days 56 and 84,
and basophils on day 84. Additionally, grade 3 to 4 aGVHD
was associated with low counts of total and naïve B cells on
day 180, nonswitched memory B cells on day 180,
CD4eCD8e T cells on day 84, NK cells on day 84, regulatory
Table 4
Associations between Immune Cell Subset Counts and aGVHV or cGVHD
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
Associations shown are those signiﬁcant in competing risks multivariate analysis in a combined (discovery and validation) cohort. [ indicates high subset count
associated with GVHD, Y indicates low subset count associated with GVHD. Light shaded boxes indicate associations signiﬁcant only when analyzing all patients
with available subset counts. Dark shaded boxes indicate associations that remained signiﬁcant after removing from analysis patients who developed aGVHD or
cGVHD before or after the blood draw date (ie, for associations at early time points (day 28 for aGVHD, and day 28, day 56 and day 84 for cGVHD). Patients
developing GVHD before the time point were removed; for associations at late time points (day 56, day 84, and day 180 for aGVHD and day 180 for cGVHD),
patients developing GVHD after the time point were removed.
* aGVHD comparison was grade 2 to 4 versus 0.
y cGVHD comparison was those needing systemic immunosuppressive therapy versus none.
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(Supplemental Figure 4).
Given the median onset of grade 2 to 4 aGVHD of day 34,
as stated above, we assumed that the high counts of total,naïve, and memory/effector CD4 T cells, and total and
memory/effector CD8 T cells on day 28 were suggestive of a
causal relation to the development of aGVHD (rather than
aGVHD or its treatment causing the high cell counts). To
Figure 1. Cumulative incidence of grade 2 to 4 acute graft-versus-host disease diagnosed after the day 28 immune cell subset count determination in patients with
high versus low subset counts on the day 28 determination. The cutoffs between high and low counts (shown as dotted horizontal lines in the small scatter plots,
right) were determined using receiver operating characteristic curves. P values shown are those obtained frommultivariate analysis. Solid horizontal lines in the small
scatter plots represent medians.
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ysis inwhich we excluded all patients developing grade 2 to
4 aGVHD before the day 28 time point (19 patients
excluded). To compensate for lost power, we combined
discovery and validation cohorts for these analyses(n ¼ 200). All associations from the original analysis (that
included patients developing aGVHD before the day 28 time
point) remained signiﬁcant (P .010) (Figure 1). We also did
an analogous analysis for grade 3 to 4 aGVHD. The results
were the same as for the original analysis except for total
P.J. Podgorny et al. / Biol Blood Marrow Transplant 20 (2014) 450e462 457B cells and regulatory NK cells, ie, the day 28 subsets
associated with subsequent grade 3 to 4 aGVHD were CD4
T cells, naïve CD4 T cells, memory/effector CD4 T cells, CD8
T cells, naïve CD8 T cells, memory/effector CD8 T cells, and
CD4eCD8e T cells (Supplemental Figure 5).
To further corroborate the presumed cause-and-effect
relationship for the later time points (grade 2 to 4
aGVHD and/or its treatment presumably resulting in the
low counts of multiple subsets on days 56, 84, or 180), we
combined discovery and validation cohorts and removed
from analysis all patients developing aGVHD after the
respective blood draw time point (excluded 15 patients forFigure 2. Immune cell subset counts on day 56, day 84, and day 180 after transplantat
diagnosed before the day of the determination of the counts. P values shown are those
Dotted horizontal lines represent receiver operating characteristic curve-derived cutoday 56, 6 for day 84, and 0 for day 180), assuring that
aGVHD was present to take effect on the cell counts. All the
associations remained signiﬁcant with this analysis, ie,
grade 2 to 4 aGVHD was associated with subsequent low
counts of B cells, naive B cell, nonswitched memory B cells,
NK cells, cytolytic NK cells, MDCs, PDCs, and basophils
(Figure 2). We also repeated this analysis for grade 3 to 4
aGVHD and found that, except for plasmacytoid cells on
day 56, CD4eCD8e T cells on day 84 and regulatory NK cells
on day 84, all associations remained signiﬁcant, ie, grade 3
to 4 aGVHD was associated with subsequent low counts of
B cells, naïve B cells, nonswitched memory B cells, NK cells,ion in patients with versus without grade 2 to 4 acute graft-versus-host disease
obtained from multivariate analysis. Solid horizontal lines represent medians.
ff values for multivariate analysis.
Figure 3. Cumulative incidence of chronic graft-versus-host disease (diag-
nosed after the day 56 subset count determination) in patients with high
versus low switched memory B cell counts on the day 56 determination. The
cutoff between high and low counts (shown as dotted horizontal lines in the
small scatter plot, right) was determined using receiver operating character-
istic curve. P value shown was obtained from multivariate analysis.
Figure 4. Cumulative incidence of chronic graft-versus-host disease diag-
nosed after the day 56 subset count determination, analogous to Figure 3.
Contrary to data presented in Figure 3, patients with possible late acute graft-
versus-host disease were excluded. The cutoff between high and low counts
(shown as dotted horizontal lines in the small scatter plot, right) was deter-
mined using receiver operating characteristic curve. P value shown was ob-
tained from multivariate analysis.
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Figure 6).
In addition to the above cell subsets, we also determined
the counts of regulatory T cells (Tregs). Unfortunately, in the
discovery cohort, the Tregs were deﬁned in an outdated way
(CD3þCD4þCD25high) whereas in the validation cohort, the
Tregs were deﬁned the way acceptable by current standards
(CD3þCD4þCD25þCD127), so we did not perform any ana-
lyses requiring the combination of the discovery and vali-
dation cohorts. In both the discovery and validation cohorts,
high Treg counts on day 28 were associated with aGVHD in
both UVA and MVA (Supplemental Figure 7). Acute GVHD
was not associated with Treg counts on days 56, 84, or 180.
Chronic GVHD
Among 75 patients who developed cGVHD, the median
onset of cGVHD was day 106 (range, 28 to 642). Thus, as-
sociations between subset counts on days 28, 56, and 84 and
cGVHD were suggestive of these subsets playing a role in
the pathogenesis of cGVHD, whereas associations between
cGVHD and subset counts on day 180were suggestive of these
subsets being inﬂuenced by the cGVHD and/or its treatment.
In the discovery cohort, cGVHD was not associated with
high counts of any cell subsets. However, low counts of the
following subsets on days 28, 56, or 84 were associated with
cGVHD: switchedmemoryBcellsonday56,monocytesonday
56, inﬂammatorymonocytes on day 56, regulatoryNK cells on
day 84, and basophils on days 28 and 84. Regarding the later
time point of day 180, cGVHDwas not associated with high or
low count of any subset on day 180. Also, cGVHD was not
associated with high or low content of any subset in the graft.
In the validation cohort, the only association that was
conﬁrmed was that of low count of switched memory B cells
on day 56 and cGVHD (Table 3, Supplemental Figure 8).
The above analyses for associations between cell subsets
and cGVHD included aGVHD as a covariate. Thus, an associ-
ation between a subset that inﬂuences the development of
both aGVHD and cGVHD may have been reported as not
associated with cGVHD. For this reason, we repeated the
analyses but excluded aGVHD from the covariates. The as-
sociation between the low counts of switched memory
B cells on day 56 and cGVHD remained signiﬁcant; however,
no other subsets were signiﬁcantly associated with cGVHD
(data not shown).
As with aGVHD, we also determined whether Tregs were
associated with cGVHD. No signiﬁcant association was found
between day 28, day 56, day 84, or day 180 Treg count and
cGVHD.
We hypothesized that the low switched memory B cell
counts on day 56 being associated with cGVHD suggested a
protective effect of the memory B cells (against cGVHD). To
corroborate this, we performed an additional analysis in
which we excluded patients developing aGVHD or cGVHD
before day 56 from our combined discovery and validation
cohort (48 patients excluded, 171 patients analyzed). The
association of low counts of memory B cells with cGVHDwas
near signiﬁcant (P ¼ .011) (Figure 3).
A limitation of our study is the use of a cGVHD deﬁni-
tion (see Methods) that allows patients with late aGVHD to
be categorized as cGVHD. We used this deﬁnition because
information in patient charts was not always complete for
unequivocal categorization of posteday 100 GVHD as acute
or chronic. To mitigate this, we repeated the analysis pre-
sented in the previous paragraph, except we also excluded
13 patients who may have had late aGVHD. This resulted inan analysis of only patients with strict cGVHD per NIH
criteria [17]. Consistent with the analysis in the previous
paragraph, cGVHD was preceded by low day 56 counts of
switched memory B cells (Figure 4).Relapse
In the discovery cohort, relapse was associated with low
CD4 T cell count on day 84 and low memory/effector CD4
T cell count on day 84. However, these ﬁndings were not
conﬁrmed in the validation cohort. As stated in the Methods,
patients were not followed for immune cell subset counts
after the diagnosis of relapse. Thus, the lack of associations
cannot be attributed to subsets being inﬂuenced by relapse
or its therapy.Death
In the discovery cohort, low counts of nonswitched
memory B cells on day 56 were associated with death. This
was not conﬁrmed in the validation cohort.
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To corroborate the possible causal relation between the
high/low subset counts before GVHD onset and GVHD, we
determined whether there was a correlation between the
count of each subset suspected of the causal relation and the
day of onset of GVHD.
For aGVHD, all the subsets suspected of playing a role in
the pathogenesis of aGVHD (per Figure 1) showed a signiﬁ-
cant inverse correlation between the day 28 subset count
and the day of onset of aGVHD (Table 5). This further sup-
ports the role of these subsets in the pathogenesis of aGVHD.
For cGVHD, the switched memory B cells, which we
suspected may play a protective role against cGVHD (per
Table 3), did not appear to display a signiﬁcant correlation
between their count and the day of onset of cGVHD (Table 5).
Steroid-responsive versus Refractory aGVHD
We also evaluated differences in cell subset counts
between patients with steroid-responsive versus steroid-
refractory aGVHD. Given the small number of patients
(n ¼ 14 for steroid refractory, n ¼ 46 for steroid responsive),
we only compared the subset counts in UVA using the MWW
test and considered P  .01 as signiﬁcant. Compared with
patients with steroid-responsive aGVHD, patients with
steroid-refractory aGVHD had lower counts of regulatory NK
cells on day 84 and myeloid dendritic cells on day 84
(Supplemental Table 1).
Associations between Cell Subset Counts and aGVHD or
cGVHD When Not Considering Patients with Clinically
Insigniﬁcant GVHD (Grade 1 aGVHD or cGVHD NNST)
The analyses of the associations between cell subset
counts and GVHD (presented in summary in Table 3), though
relatively high in power, have the ﬂaw of comparing patients
with grade 2 to 4 aGVHD with patients with grade 0 to 1
aGVHD, instead of a purer group of only patients with grade
0 aGVHD and, analogously, comparing patients with cGVHD
NST to patients with no cGVHD or cGVHD NNST, instead of a
purer group of only patients with no cGVHD. To address this
issue, using combined (discovery and validation) cohort, we
reran the analyses comparing patients with grade 2 to 4
aGVHD to only patients with grade 0 aGVHD, and comparing
patients with cGVHDNST to only patients with no cGVHD. All
conclusions remained valid, except for the association be-
tween basophil counts on day 84 and aGVHD (Table 4). In
addition, several new associations appeared in this analysis
(Table 4). High counts of the following subsets on day 28
preceded clinical aGVHD: CD4 T cells, naïve CD4 T cells,
memory/effector CD4 T cells, CD8 T cells, naïve CD8 T cells,
memory/effector CD8 T cells, and CD4eCD8e T cells. After
aGVHD (on day 56 or 84), the following subsets were low:
CD8 T cells, memory/effector CD8 T cells, CD4eCD8e T cells,Table 5
Correlations between Immune Subset Counts and the Day of GVHD Onset
Cell Subset Spearman
Correlation
Coefﬁcient
(r)
Signiﬁcance
(P)
aGVHD CD4 T on day 28 .5137 .0007
Memory/effector CD4 T on day 28 .5231 .0005
CD8 T on day 28 .5915 <.0001
Memory/effector CD8 T on day 28 .5808 <.0001
cGVHD Switched memory B on day 56 .03724 ns
GVHD indicates graft-versus-host disease; aGVHD, acute graft-versus-host
disease; cGVHD, chronic graft-versus-host disease; ns, not signiﬁcant.NK cells, regulatory NK cells, cytolytic NK cells, PDCs, and
neutrophils. Chronic GVHDwas preceded by high day 28, day
56, and day 84 counts of CD4 T cells, memory/effector CD4
T cells, naïve CD8 T cells, CD4eCD8e T cells CD4þCD8þ T cells
and low day 28, day 56, and day 84 counts of switched
memory B cells, monocytes, inﬂammatory monocytes, and
regulatory NK cells.
Comparison of Patients with Grade 0 versus Grade 1
aGVHD and Patients with No cGVHD versus cGVHD NNST
The above evaluation of the effect of aGVHD on the day
56, day 84, and day 180 immune cell subset counts and of the
effect of cGHVD on day 180 subset counts has the ﬂaw of not
being able to separate the effect of GVHD itself from the ef-
fect of systemic immunosuppressive therapy for the GVHD.
In an attempt to circumvent this ﬂaw, we compared day 56,
day 84, and day 180 subset counts in patients with aGVHD
grade 0 versus grade 1 (not treated with systemic immuno-
suppressive drugs). We used the MWW test and combined
discovery and validation cohort patients. In patients with
grade 1 aGVHD, there were signiﬁcantly higher counts of
nonswitched memory B cells on day 84, naïve CD8 T cells on
day 84, monocytes on day 56, and inﬂammatory monocytes
on day 56 (data not shown). We also compared day 180
subset counts in patients with no cGVHD versus cGVHD
NNST. In patients with cGVHD NNST, there was signiﬁcantly
higher median count of switched memory B cells and naïve
CD8 T cells on day 180 (data not shown).
DISCUSSION
Here we present data on association between immune
cell subset counts and GVHD in >200 patients. Two major
analyses are presented: (1) the comparison of patients with
clinically signiﬁcant GVHD versus patients with clinically
insigniﬁcant or no GVHD (grade 2 to 4 versus 0 to 1 aGVHD,
and cGVHD NST versus no cGVHD or cGVHD NNST) (Table 3),
and (2) the comparison of patients with clinically signiﬁcant
GVHD versus no GVHD (grade 2 to 4 versus 0 aGHVD, and
cGVHD NST versus no cGVHD) (Table 4). The former analysis
has the advantage of a sufﬁcient number of patients allowing
discovery-to-validation design, and the advantage of clinical
relevance, but it has the disadvantage of “impure” reference
group. The latter analysis has the advantage of “pure” refer-
ence group, but the disadvantage of no validation. In the
forthcoming paragraphs, we will weigh highly associations
found in both analyses, but also comment on salient associ-
ations found in only 1 of the 2 analyses.
Important ﬁndings of this study are the following: (1)
high counts of total, naïve, or memory/effector CD4 T cells
and total, naïve, or memory/effector CD8 T cells precede
aGVHD and, likely, also cGVHD, suggesting a role for both CD4
and CD8 T cells in the pathogenesis of human aGVHD and
cGVHD; (2) cGVHD is preceded by low counts of switched
memory B cells and, likely, also total and inﬂammatory
monocytes and regulatory NK cells, suggesting an anti-
cGVHD effect for these cells; and (3) aGVHD is followed by
low counts of multiple cell subsets, speciﬁcally total and
cytolytic NK cells, PDCs, and, likely, also total and naïve
B cells, total and memory/effector CD8 T cells, CD4eCD8e
T cells, total and inﬂammatory monocytes, MDCs, basophils,
and neutrophils, suggesting that aGVHD or its treatment
hampers the generation of multiple immune cell subsets.
It is not known whether human aGVHD or cGVHD is
caused by CD4 or CD8 T cells. In mice, aGVHD can be caused
by CD4 and/or CD8 Tcells [20]. Our data strongly suggest that
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adequate mouse models are lacking. Our data suggest that,
similar to aGVHD, human cGVHDmay be caused by CD4 and/
or CD8 T cells (Table 4).
Naive CD4 T cells were increased before grade 2 to 4
aGVHD as compared with patients without aGVHD (Table 4)
and naïve CD8 T cells were increased before cGVHD NST
as compared with no cGVHD (Table 4). Naïve T cells (both
CD4 and CD8) were also high in patients with grade 3 to 4
aGVHD (Supplemental Figure 5). This is intriguing, as allor-
eactive naive T cells, which were infused with the graft and
survived exposure to ATG, are expected to have differenti-
ated between day 0 and day 28 or 84 into memory/effector
cells, as between day 0 and day 28 or 84 the naive cells were
exposed to alloantigens. This expectation is consistent with
our ﬁnding of high memory/effector CD4 and CD8 T cell
counts preceding aGVHD (Tables 3-5, and Supplemental
Figure 5) and high memory/effector CD4 T cell counts likely
preceding cGVHD (Table 4). Perhaps, the naive CD4 T cells
detected at 1 to 3 months after transplantation are non-
alloreactive, but their number serves as a surrogate for the
number of total (alloreactive and nonalloreactive) naive
T cells that were infused with the graft and survived the
exposure to ATG. It is unlikely that the naïve cells were
generated in the thymus from grafted hematopoietic stem
cells, as thymopoiesis in adult HCT recipients with GVHD
typically starts at > 3 months after transplantation [21-23].
We cannot exclude the possibility that using the naive
T cell deﬁnition of CD45RAþ and CD11Alow, in addition to
naive T cells, we included also memory T stem cells [24-26]
in the naive T cell gate. If that were the case, the “naive”
T cells measured by us in post-transplantation blood could
be a mixture of naive T cells (possibly nonalloreactive)
and memory T stem cells, which may have differentiated
from alloreactive naive T cells after encountering their
cognate alloantigens in the recipient. In mice, naive (and not
memory/effector) T cells cause aGVHD [27-34]. Per a human
in vitro study, naive Tcells are rich in Tcells speciﬁc for minor
histocompatibility alloantigens, the target of graft-versus-
host reaction in the HLA-matched transplantation setting
[35]. To our knowledge, our observation is the ﬁrst one
supporting the role of naive T cells in the pathogenesis of
both aGVHD and cGVHD in humans in vivo. This, together
with our observation that naive T cell counts were not
associated with relapse, emphasizes the importance of
clinical trials evaluating whether naive T cell depletion
reduces aGVHD and cGVHD without increasing relapse
(NCT01625351 by D.R. Shook, St. Jude’s Children’s Research
Hospital; NCT00914940 by M. Bleakley, Fred Hutchinson
Cancer Research Center, and W. Schlomchik, Yale University;
NCT00914940 by M. Horwitz, Duke University).
Regulatory CD4 T cells (Tregs) were increased before
aGVHD onset. This is counterintuitive. Our understanding of
Tregs may be incomplete. Consistent with our ﬁnding,
increased Tregs in patients with GVHD have been reported
in some [36,37] but not other studies [38-41]. Perhaps, in
our patients, the Tregs were generated in an effort to miti-
gate the GVHD [42].
An anti-cGVHD effect of switched memory B cells is sus-
pected, based on the ﬁnding that cGVHD was less likely to
develop in patients in whom day 56 counts of these cells
were increased (Figures 3, 4). The potential anti-cGVHD ef-
fect of a B cell subset is surprising, as it is generally believed
that B cells contribute to the pathogenesis of GVHD [6,43]. A
possible explanation might be that memory B cells, potentproducers of interleukin-10 (IL-10) [44], inhibit alloreactive
T cells or regulate other immune cells to suppress GVHD [45-
48]. This regulatory function is supported by ﬁndings that
B cell depletion in patients for autoimmune disease with
rituximab appears to be detrimental and may unmask a
second autoimmune disease [49,50]. These ﬁndings have a
translational potential. If the association between low
memory B cells early after transplantation and cGVHD is
conﬁrmed in another study, infusions of memory B cells
should be studied in patients at high risk of developing
cGVHD. Moreover, mechanistic studies are needed to deter-
mine whether the memory B cellemediated protection from
cGVHD is due to the secretion of IL-10. If so, a clinical trial of
IL-10 in patients at high risk for developing cGVHD should be
considered. Interestingly, regulatory NK cells and inﬂam-
matory monocytes might also have anti-cGVHD effect
(Table 4), and these subsets are also known to exert
IL10emediated suppression of T cells (including alloreactive
T cells) [51-54].
A negative impact of aGVHD or its treatment on subse-
quent counts of total and cytolytic NK cells, PDCs, and likely
also total and naïve B cells, total and memory/effector CD8
T cells, CD4eCD8e T cells, total and inﬂammatory monocytes,
MDCs, basophils, and neutrophils was noted (Tables 3, 4,
Figure 2, Supplemental Figure 6). The negative impact on
naive B cells would be consistent with the known negative
effect of aGVHD or its treatment on B-lymphopoiesis [55].
The negative impact on memory/effector CD8 T cells would
be consistent with the known negative effect of aGVHD or
corticosteroids on CD8 T cell proliferation/differentiation
[56]. To our knowledge, this is the ﬁrst report noting the
negative impact of aGVHD or its treatment on NK cells and
PDCs and, possibly, also monocytes, MDCs, basophils, and
neutrophils. Perhaps, their low counts may be related to the
destruction of hematopoietic niches in marrow by aGVHD
[57]. As NK cells, PDCs, monocytes, MDCs, basophils, and
neutrophils play a role in antimicrobial defense [58-62], the
deﬁciency of these cells might contribute to the high rates of
infections in patients with aGVHD.
The lack of association between cGVHD and the counts of
any cell subset on day 180 does not necessarily mean that
cGVHD or its treatment had no inﬂuence on immune cell
subset counts. A substantial number of patients developed
cGVHD after day 180, so it is possible that cGVHD could
inﬂuence subset counts at a later time point. Even for pa-
tients who developed cGVHD before day 180, the effect on
immune cell subset counts may have not fully developed by
day 180, but could have developed by a later time point. In a
limited number of patients, we measured the subset counts
at 1 year after transplantation (n ¼ 49) and found in UVA
that cGVHD appeared to be associated with low counts of
the following subsets at 1 year: naïve B cells, regulatory NK
cells, PDCs, and basophils (P < .05 in UVA, data not shown).
However, these associations were no longer signiﬁcant after
MVA.
The lack of association between the graft content of any
subset and GVHD is contrary to previous reports on patients
who did not receive any form of in vivo T cell depletion
[3,4,9,63,64]. It is possible that in our patients, all of whom
received ATG, there was a high variability in the degree of
depletion of Tcells or other immune cells playing a role in the
pathogenesis of GVHD by the ATG [65,66], and that this
variability overshadowed the variability in graft contents.
A limitation of our study was its limited power. Although
this is the largest study of its kind to date, the lack of
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interpreted as the absence of cause-and-effect relationship
between the subset and GVHD. This is not only because of the
limited power of our study but also because the absence of a
quantitative subset alteration related to GVHD does not
preclude the presence of a qualitative (functional) one.
Moreover, the absence of quantitative alteration of a cell
subset in blood does not preclude the presence of a quanti-
tative or qualitative alteration of the subset in tissues.
Another limitation of our study is the classiﬁcation of
aGVHD and cGVHD based on historical criteria. Nevertheless,
the lack of effect of the elimination of patients with possible
late aGVHD from analysis on the conclusions (Figures 3, 4)
strongly suggests that the conclusions presented here also
apply to NIH criteriaedeﬁned cGVHD.
Another limitation of our study is the use of fresh cells in
the discovery cohort versus cryopreserved cells in the vali-
dation cohort. Thus, it is possible that an association between
the count of a subset sensitive to freezing/thawing damage
and GVHD may have been observed in the discovery cohort
but falsely not validated in the validation cohort. This could
apply to high day 28 counts of the following subsets in
relation to aGVHD: naive CD8 T cells and CD4CD8 T cells.
This could also apply to low day 28, day 56, or day 84 counts
of the following subsets in relation to cGVHD: monocytes on
day 56, resident monocytes on day 56, regulatory NK cells on
day 84, PDCs on day 84, and basophils on day 28.
In conclusion, our results suggest that both CD4 and CD8
T cells play a role in the pathogenesis of both aGVHD and
cGVHD in humans, and that the causative effect of naive
T cells on aGVHD reported in mice applies also to human
aGVHD and cGVHD. This supports the importance of clinical
trials evaluating whether aGVHD and cGVHD can be mini-
mized by using grafts depleted of naive T cells. In addition, if
the presumed anti-cGVHD effect of memory B cells (or reg-
ulatory NK cells or inﬂammatory monocytes) is conﬁrmed in
other studies, this could result in clinical trials of infusions of
these cells (prepared from donor blood) to patients at high
risk of developing cGVHD. Moreover, if the proposed aGVHD
and/or aGVHD treatment-induced damage to the production
of multiple immune cell subsets and its relation to aGVHD-
associated infections are demonstrated in other studies,
this could result in clinical trials evaluating whether the rate
of aGVHD-associated infections could be mitigated by
replacement of some of the subsets from donor blood.
ACKNOWLEDGMENTS
The authors thank the patients for participating in
research that could not beneﬁt them but only future patients.
We thank Polly Louie, Lynne Fisk, Judy Wu, Glennis Doiron,
Feng Zhou, Monja Metcalf, as well as the staff of the Alberta
Blood and Marrow Transplant Program, including inpatient
and outpatient nurses (lead by Lorraine Harrison, Joanne
Leavitt and Naree Ager) and physicians, including Drs. M.
Ahsan Chaudhry, Andrew Daly, Douglas A. Stewart, Nancy
Zacarias, Ping Yue, Nizar Bahlis, Chris Brown, Peter Duggan,
Michelle Geddes, Lynn Savoie, Mona Shafey, Loree Larratt,
and Robert Turner.
Financial disclosure: This work was funded by Alberta
Heritage Foundation for Medical Research, Canada Research
Chair Program and Alberta Cancer Foundation.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Authorship statement: P.J.P. participated in the determi-
nation of the cell subset counts, performed the statisticalanalyses and wrote the manuscript. Y.L. and P.D. determined
the cell subset counts. L.M.P., J.L., I.A., and A.M. participated in
the determination of the cell subset counts. T.S.W. designed
the statistical analysis. A.U., K.J., and M.H.P. extracted the
clinical data. D.A.S., A.D., F.M.K., and J.A.R. critically reviewed
the manuscript. J.S. designed the study, supervised its
conduct, and extensively edited the manuscript.SUPPLEMENTARY DATA
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.bbmt.2014.01.002.REFERENCES
1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease
biology and therapy. Nat Rev Immunol. 2012;12:443-458.
2. Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-
versus-host disease. Immunol Allergy Clin North Am. 2010;30:75-101.
3. Heimfeld S, Gooley T, Flowers M, et al. Effect of peripheral blood stem
cell graft composition on graft versus host diseases and mortality after
allogeneic transplantation. Blood. 2010;116:676.
4. McIver ZA, Melenhorst JJ, Grim A, et al. Immune reconstitution in re-
cipients of photodepleted HLA-identical sibling donor stem cell trans-
plantations: T cell subset frequencies predict outcome. Biol Blood
Marrow Transplant. 2011;17:1846-1854.
5. Yakoub-Agha I, Saule P, Depil S, et al. A high proportion of donor CD4þ
T cells expressing the lymph node-homing chemokine receptor CCR7
increases incidence and severity of acute graft-versus-host disease in
patients undergoing allogeneic stem cell transplantation for hemato-
logical malignancy. Leukemia. 2006;20:1557-1565.
6. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-
Baildon MS. The role of B cells in the pathogenesis of graft-versus-host
disease. Blood. 2009;114:4919-4927.
7. Christopeit M, Schutte V, Theurich S, et al. Rituximab reduces the inci-
dence of acute graft-versus-host disease. Blood. 2009;113:3130-3131.
8. Fraser AR, Cook G, Franklin IM, et al. Immature monocytes from G-CSF-
mobilized peripheral blood stem cell collections carry surface-bound
IL-10 and have the potential to modulate alloreactivity. J Leukoc Biol.
2006;80:862-869.
9. Chaidos A, Patterson S, Szydlo R, et al. Graft invariant natural killer
T-cell dose predicts risk of acute graft-versus-host disease in allogeneic
hematopoietic stem cell transplantation. Blood. 2012;119:5030-5036.
10. Novitzky N, Davison GM, Hale G, Waldmann H. Immune reconstitution
at 6 months following T-cell depleted hematopoietic stem cell trans-
plantation is predictive for treatment outcome. Transplantation. 2002;
74:1551-1559.
11. Rajasekar R, Mathews V, Lakshmi KM, et al. Plasmacytoid dendritic cell
count on day 28 in HLA-matched related allogeneic peripheral blood
stem cell transplant predicts the incidence of acute and chronic GVHD.
Biol Blood Marrow Transplant. 2008;14:344-350.
12. Watanabe N, Narita M, Furukawa T, et al. Kinetics of pDCs, mDCs,
gammadeltaT cells and regulatory T cells in association with graft
versus host disease after hematopoietic stem cell transplantation. Int
J Lab Hematol. 2011;33:378-390.
13. Rubio MT, Moreira-Teixeira L, Bachy E, et al. Early posttransplantation
donor-derived invariant natural killer T-cell recovery predicts the
occurrence of acute graft-versus-host disease and overall survival.
Blood. 2012;120:2144-2154.
14. Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched
related donor blood cell transplants given myeloablative regimens
including pretransplant antithymocyte globulin have lower mortality
related to graft-versus-host disease: a matched pair analysis. Biol Blood
Marrow Transplant. 2007;13:299-306.
15. Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for
adult acute leukemia in ﬁrst and second remission with a novel
regimen incorporating daily intravenous busulfan, ﬂudarabine, 400
CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow
Transplant. 2007;13:814-821.
16. Ugarte-Torres A, Hoegh-Petersen M, Liu Y, et al. Donor serostatus has
an impact on cytomegalovirus-speciﬁc immunity, cytomegaloviral
disease incidence, and survival in seropositive hematopoietic cell
transplant recipients. Biol Blood Marrow Transplant. 2011;17:574-585.
17. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and staging working group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference
on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
19. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host
syndrome in man. A long-term clinicopathologic study of 20 Seattle
patients. Am J Med. 1980;69:204-217.
P.J. Podgorny et al. / Biol Blood Marrow Transplant 20 (2014) 450e46246220. Korngold R, Friedman TM. Murine models of graft-vs-host disease and
graft-vs-tumor effect. In: Appelbaum FR, Forman SJ, Negrin RS,
Blume KG, editors. Thomas’ Hematopoietic Cell Transplantation. West
Sussex, UK: Wiley-Blackwell; 2009. p. 176-187.
21. Storek J, Joseph A, Dawson MA, et al. Factors inﬂuencing T-lympho-
poiesis after allogeneic hematopoietic cell transplantation. Trans-
plantation. 2002;73:1154-1158.
22. Castermans E, Hannon M, Dutrieux J, et al. Thymic recovery after
allogeneic hematopoietic cell transplantation with non-myeloablative
conditioning is limited to patients younger than 60 years of age.
Haematologica. 2011;96:298-306.
23. Clave E, Busson M, Douay C, et al. Acute graft-versus-host disease
transiently impairs thymic output in young patients after allogeneic
hematopoietic stem cell transplantation. Blood. 2009;113:6477-6484.
24. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem
cell-like properties. Nat Med. 2011;17:1290-1297.
25. Lugli E, Gattinoni L, Roberto A, et al. Identiﬁcation, isolation and in vitro
expansion of human and nonhuman primate T stem cell memory cells.
Nat Protoc. 2013;8:33-42.
26. Zhang Y, Joe G, Hexner E, et al. Host-reactive CD8þ memory stem cells
in graft-versus-host disease. Nat Med. 2005;11:1299-1305.
27. Xystrakis E, Bernard I, Dejean AS, et al. Alloreactive CD4 T lymphocytes
responsible for acute and chronic graft-versus-host disease are con-
tained within the CD45RChigh but not the CD45RClow subset. Eur
J Immunol. 2004;34:408-417.
28. Spickett GP, Brandon MR, Mason DW, et al. MRC OX-22, a monoclonal
antibody that labels a new subset of T lymphocytes and reacts with the
high molecular weight form of the leukocyte-common antigen. J Exp
Med. 1983;158:795-810.
29. Chen BJ, Cui X, Sempowski GD, et al. Transfer of allogeneic CD62L-
memory T cells without graft-versus-host disease. Blood. 2004;103:
1534-1541.
30. Anderson BE, McNiff J, Yan J, et al. Memory CD4þ T cells do not induce
graft-versus-host disease. J Clin Invest. 2003;112:101-108.
31. Zhang Y, Joe G, Zhu J, et al. Dendritic cell-activated CD44hiCD8þ T cells
are defective in mediating acute graft-versus-host disease but retain
graft-versus-leukemia activity. Blood. 2004;103:3970-3978.
32. Zhang P, Wu J, Deoliveira D, et al. Allospeciﬁc CD4(þ) effector memory
T cells do not induce graft-versus-host disease in mice. Biol Blood
Marrow Transplant. 2012;18:1488-1499.
33. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in
acute graft-versus-host disease reveal sequential inﬁltration of T-cell
subsets. Blood. 2005;106:1113-1122.
34. Moncrieffe H, Coles M, Stockinger B. The inﬂuence of CD4 T-cell subsets
on control of CD4 T-cell-mediated graft-versus-host disease. Immu-
nology. 2008;125:459-468.
35. Bleakley M, Otterud BE, Richardt JL, et al. Leukemia-associated
minor histocompatibility antigen discovery using T-cell clones iso-
lated by in vitro stimulation of naive CD8þ T cells. Blood. 2010;115:
4923-4933.
36. Lord JD, Hackman RC, Gooley TA, et al. Blood and gastric FOXP3þ T cells
are not decreased in human gastric graft-versus-host disease. Biol
Blood Marrow Transplant. 2011;17:486-496.
37. Clark FJ, Gregg R, Piper K, et al. Chronic graft-versus-host disease is
associated with increased numbers of peripheral blood CD4þCD25high
regulatory T cells. Blood. 2004;103:2410-2416.
38. Meignin V, Peffault de Latour R, Zuber J, Regnault A, Mounier N,
Lemaitre F, Dastot H, Itzykson R, Devergie A, Cumano A, Gluckman E,
Janin A, Bandeira A, Socie G. Numbers of Foxp3-expressing
CD4þCD25high T cells do not correlate with the establishment of long-
term tolerance after allogeneic stem cell transplantation. Exp Hematol.
2005;33:894-900.
39. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC,
Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD. Associ-
ation of Foxp3 regulatory gene expression with graft-versus-host dis-
ease. Blood. 2004;104:2187-2193.
40. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J,
Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ. High donor
FOXP3-positive regulatory T-cell (Treg) content is associated with a
low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;
108:1291-1297.
41. Zhai Z, Sun Z, Li Q, Zhang A, Liu H, Xu J, Xu X, Geng L, Harris D, Hu S,
Wang Y. Correlation of the CD4þCD25high T-regulatory cells in re-
cipients and their corresponding donors to acute GVHD. Transpl Int.
2007;20:440-446.42. Beres AJ, Haribhai D, Chadwick AC, et al. CD8þ Foxp3þ regulatory
T cells are induced during graft-versus-host disease and mitigate dis-
ease severity. J Immunol. 2012;189:464-474.
43. Kim SJ, Won JH. B cell homeostasis and the development of chronic
graft-versus-host disease: implications for B cell-depleting therapy.
Leuk Lymphoma. 2012;53:19-25.
44. Bouaziz JD, Calbo S, Maho-Vaillant M, et al. IL-10 produced by activated
human B cells regulates CD4(þ) T-cell activation in vitro. Eur J Immunol.
2010;40:2686-2691.
45. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10
following TBI and attenuate acute GVHD after allogeneic bone
marrow transplantation. Blood. 2006;108:2485-2492.
46. Wong SC, Puaux AL, Chittezhath M, et al. Macrophage polarization to a
unique phenotype driven by B cells. Eur J Immunol. 2010;40:2296-2307.
47. Le Huu D, Matsushita T, Jin G, et al. Donor-derived regulatory B cells are
important for suppression of murine sclerodermatous chronic graft-
versus-host disease. Blood. 2013;121:3274-3283.
48. van de Veen W, Stanic B, Yaman G, et al. IgG4 production is conﬁned to
human IL-10-producing regulatory B cells that suppress antigen-speciﬁc
immune responses. J Allergy Clin Immunol. 2013;131:1204-1212.
49. Goetz M, Atreya R, Ghalibaﬁan M, et al. Exacerbation of ulcerative
colitis after rituximab salvage therapy. Inﬂamm Bowel Dis. 2007;13:
1365-1368.
50. Dass S, Vital EM, Emery P. Development of psoriasis after B cell
depletion with rituximab. Arthritis Rheum. 2007;56:2715-2718.
51. Said EA, Dupuy FP, Trautmann L, et al. Programmed death-1-induced
interleukin-10 production by monocytes impairs CD4þ T cell activa-
tion during HIV infection. Nat Med. 2010;16:452-459.
52. Gama L, Shirk EN, Russell JN, et al. Expansion of a subset of
CD14highCD16negCCR2low/neg monocytes functionally similar to
myeloid-derived suppressor cells during SIV and HIV infection. J Leukoc
Biol. 2012;91:803-816.
53. Walter GJ, Evans HG, Menon B, et al. Interaction with activated
monocytes enhances cytokine expression and suppressive activity of
human CD4þCD45roþCD25þCD127(low) regulatory T cells. Arthritis
Rheum. 2013;65:627-638.
54. Geissmann F, Auffray C, Palframan R, et al. Blood monocytes: distinct
subsets, how they relate to dendritic cells, and their possible roles in
the regulation of T-cell responses. Immunol Cell Biol. 2008;86:398-408.
55. Storek J, Wells D, Dawson MA, et al. Factors inﬂuencing B lympho-
poiesis after allogeneic hematopoietic cell transplantation. Blood. 2001;
98:489-491.
56. Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ. Graft-
versus-host disease impairs vaccine responses through decreased
CD4þ and CD8þ T cell proliferation and increased perforin-mediated
CD8þ T cell apoptosis. J Immunol. 2013;190:1351-1359.
57. Shono Y, Ueha S, Wang Y, et al. Bone marrow graft-versus-host disease:
early destruction of hematopoietic niche after MHC-mismatched he-
matopoietic stem cell transplantation. Blood. 2010;115:5401-5411.
58. Garcia-Penarrubia P, Koster FT, Kelley RO, et al. Antibacterial activity of
human natural killer cells. J Exp Med. 1989;169:99-113.
59. Walzer T, Dalod M, Vivier E, Zitvogel L. Natural killer cell-dendritic cell
crosstalk in the initiation of immune responses. Expert Opin Biol Ther.
2005;5(Suppl 1):S49-S59.
60. Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense
against microbial pathogens. Annu Rev Immunol. 2008;26:421-452.
61. Sundquist M, Johansson C, Wick MJ. Dendritic cells as inducers of
antimicrobial immunity in vivo. APMIS. 2003;111:715-724.
62. Sokol CL, Medzhitov R. Emerging functions of basophils in protective
and allergic immune responses. Mucosal Immunol. 2010;3:129-137.
63. Perez-Martinez A, Iyengar R, Gan K, et al. Blood dendritic cells suppress
NK cell function and increase the risk of leukemia relapse after he-
matopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;
17:598-607.
64. Rajasekar R, Lakshmi KM, George B, et al. Dendritic cell count in the
graft predicts relapse in patients with hematologic malignancies un-
dergoing an HLA-matched related allogeneic peripheral blood stem cell
transplant. Biol Blood Marrow Transplant. 2010;16:854-860.
65. Podgorny PJ, Ugarte-Torres A, Liu Y, et al. High rabbit-antihuman
thymocyte globulin levels are associated with low likelihood of graft-
vs-host disease and high likelihood of posttransplant lymphoprolifer-
ative disorder. Biol Blood Marrow Transplant. 2010;16:915-926.
66. Hoegh-Petersen M, Amin MA, Liu Y, et al. Anti-thymocyte globulins
capable of binding to T and B cells reduce graft-vs-host disease without
increasing relapse. Bone Marrow Transplant. 2013;48:105-114.
